WO2014119989A3 - Pharmaceutical composition comprising an angiotensin ii-receptor antagonist and a calcium channel blocker for the treatment of arterial hypertension - Google Patents

Pharmaceutical composition comprising an angiotensin ii-receptor antagonist and a calcium channel blocker for the treatment of arterial hypertension Download PDF

Info

Publication number
WO2014119989A3
WO2014119989A3 PCT/MX2014/000034 MX2014000034W WO2014119989A3 WO 2014119989 A3 WO2014119989 A3 WO 2014119989A3 MX 2014000034 W MX2014000034 W MX 2014000034W WO 2014119989 A3 WO2014119989 A3 WO 2014119989A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiotensin
treatment
pharmaceutical composition
receptor antagonist
calcium channel
Prior art date
Application number
PCT/MX2014/000034
Other languages
Spanish (es)
French (fr)
Other versions
WO2014119989A2 (en
Inventor
Miguel Ángel GARCIA PÉREZ
Gabriel MARCELÍN JIMÉNEZ
Concepción Albina VÁZQUEZ FLORES
Laura Ivonne GALO MOJICA
Alionka Citlalli P. ANGELES MORENO
Octavio CARO RODRÍGUEZ
Original Assignee
Garcia Pérez Miguel Ángel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garcia Pérez Miguel Ángel filed Critical Garcia Pérez Miguel Ángel
Publication of WO2014119989A2 publication Critical patent/WO2014119989A2/en
Publication of WO2014119989A3 publication Critical patent/WO2014119989A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention concerns a pharmaceutical composition in tablet-tablet form having at least two phases and comprising an inner tablet which has zero order kinetics for at least one calcium channel blocking agent and an outer tablet which has zero order kinetics and/or order one kinetics without a delay time for at least one angiotensin II-receptor antagonist. The composition can be used for the treatment of arterial hypertension, congestive cardiac insufficiency, unstable angina pectoris, acute myocardial infarction, diabetic nephropathy or associated disorders.
PCT/MX2014/000034 2013-01-31 2014-01-30 Pharmaceutical composition comprising an angiotensin ii-receptor antagonist and a calcium channel blocker for the treatment of arterial hypertension WO2014119989A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2013001277A MX2013001277A (en) 2013-01-31 2013-01-31 Pharmaceutical composition comprising an angiotensin ii-receptor antagonist and a calcium channel blocker for the treatment of arterial hypertension.
MXMX/A/2013/001277 2013-01-31

Publications (2)

Publication Number Publication Date
WO2014119989A2 WO2014119989A2 (en) 2014-08-07
WO2014119989A3 true WO2014119989A3 (en) 2014-11-27

Family

ID=51263089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2014/000034 WO2014119989A2 (en) 2013-01-31 2014-01-30 Pharmaceutical composition comprising an angiotensin ii-receptor antagonist and a calcium channel blocker for the treatment of arterial hypertension

Country Status (2)

Country Link
MX (1) MX2013001277A (en)
WO (1) WO2014119989A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
WO2007001065A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Method for the preparation of a wet granulated drug product
WO2008044862A1 (en) * 2006-10-10 2008-04-17 Hanall Pharmaceutical Co., Ltd. Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory
WO2010065492A1 (en) * 2008-12-02 2010-06-10 Sciele Pharma, Inc. Alpha2-adrenergic agonist a calcium channel blocker composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
WO2007001065A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Method for the preparation of a wet granulated drug product
WO2008044862A1 (en) * 2006-10-10 2008-04-17 Hanall Pharmaceutical Co., Ltd. Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory
WO2010065492A1 (en) * 2008-12-02 2010-06-10 Sciele Pharma, Inc. Alpha2-adrenergic agonist a calcium channel blocker composition

Also Published As

Publication number Publication date
WO2014119989A2 (en) 2014-08-07
MX2013001277A (en) 2014-07-30

Similar Documents

Publication Publication Date Title
EP3539963A4 (en) Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
EP3315608A4 (en) Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
CL2014001779A1 (en) Compounds derived from substituted fused pyrimidines and triazines; preparation procedure; Pharmaceutical composition and its use in the treatment and / or prevention of heart failure, angina pectoris, hypertension, among other diseases.
EP3259272A4 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
EP3246328A4 (en) Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof
CL2014000504A1 (en) Compounds derived from substituted condensed pyrimidines; preparation procedure; pharmaceutical composition; and use in the treatment and / or prevention of heart failure, angina pectoris, hypertension, among other diseases.
CL2014001389A1 (en) Bicyclic derivatives of dihydroisoquinolin-1-one; obtaining process; pharmaceutical composition; and its use for the treatment or prophylaxis of chronic kidney diseases, congestive heart failure, hypertension, primary aldosteronism and cushing syndrome.
EP3290420A4 (en) Pyrimidine pyrrole compound, preparation method therefor, pharmaceutical composition, and uses thereof
CL2018000565A1 (en) Compounds derived from pyridinone dicarboxamide, bromodomain inhibitors; pharmaceutical composition; pharmaceutical combination; Useful in the treatment of autoimmune, inflammatory, viral and cancer diseases, among others.
EP3380456A4 (en) Complex of angiotensin receptor antagonist and neutral endopeptidase inhibitor
EP3278803A4 (en) Solid pharmaceutical dosage form of parp inhibitor, and application of solid pharmaceutical dosage form of parp inhibitor
WO2011009890A3 (en) Use of azabicycloalkyl derivatives or pyrrolidine - 2 - one derivatives for the treatment or prevention of ataxia
TR201903101T4 (en) Treatment of myocardial infarction using TGF-beta antagonists.
EA201370219A1 (en) ANTI-HYPERTONIC PHARMACEUTICAL COMPOSITION
EP3535432A4 (en) Multiphase, cold-rolled ultra-high strength steel
IL261982B (en) Preventive and curative peroxometallate based composition, notably pharmaceutical composition
EP3320903A4 (en) Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin
EP3402488A4 (en) Solid oral dosage forms of eslicarbazepine
EP3184113A4 (en) Pharmaceutical composition, comprising gold compound, for preventing or treating liver fibrosis or liver cirrhosis
PH12014502876A1 (en) Pharmaceutical composition containing fimasartan and hydrochlorothiazide
EP3222622A4 (en) Transition metal compound and catalyst composition containing same
EP3449924A4 (en) Composition, crocins active site, and uses thereof
EP3371589A4 (en) Interfacial nanofibril composite for selective alkane vapor detection
EP3538124A4 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
EP3298161A4 (en) Methods, systems, and compositions for determining blood clot formation, and uses thereof

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14746267

Country of ref document: EP

Kind code of ref document: A2